Impact of KRAS Mutations on Colorectal Cancer Management
Author Information
Author(s): Kevin M. Sullivan, Peter S. Kozuch
Primary Institution: Albert Einstein College of Medicine
Hypothesis
KRAS wild-type status is necessary for a response to anti-EGFR monoclonal antibody therapy in colorectal cancer.
Conclusion
The study concludes that only patients with KRAS wild-type tumors benefit from anti-EGFR monoclonal antibody therapies.
Supporting Evidence
- KRAS mutations predict lack of response to anti-EGFR monoclonal antibodies.
- Only a subset of patients with colorectal cancer respond to anti-EGFR therapy.
- Evaluation of KRAS status is essential for treatment planning in metastatic colorectal cancer.
Takeaway
Some medicines for colon cancer only work if the cancer doesn't have certain mutations. If it does, those medicines won't help.
Methodology
The article reviews existing literature and clinical trials regarding KRAS mutations and their impact on treatment outcomes in colorectal cancer.
Potential Biases
Potential bias in the selection of studies reviewed and the interpretation of their results.
Limitations
The study primarily focuses on KRAS mutations and may not address other genetic factors affecting treatment response.
Participant Demographics
The study discusses various patient populations with colorectal cancer but does not provide specific demographic data.
Statistical Information
P-Value
0.013
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website